Abstract
Introduction
Most patients with limited disease small cell lung cancer (LD-SCLC) receive definitive radiochemotherapy. Some patients cannot withstand combined modality treatments. Patients with short life expectancies should receive less time-consuming programs. For patients with favorable prognoses, cure while avoiding late toxicity is important. Personalized treatment programs are required. An instrument to estimate the survival after radiochemotherapy of LD-SCLC was created.
Methods
Seventy-one patients receiving definitive radiochemotherapy for LD-SCLC were retrospectively analyzed. Eight factors were evaluated for survival including gender, age, Karnofsky performance score, T-stage, N-stage, tumor substage, number of pack years, and pre-radiotherapy hemoglobin level. Factors that were significant (p < 0.05) or showed a trend (p ≤ 0.08) on multivariate analyses were incorporated in the score. Scoring points were derived from 2-year survival rates divided by 10 and added to scores for individual patients.
Results
On multivariate analysis, gender (p = 0.03), performance score (p < 0.001), and pre-radiotherapy hemoglobin level (p = 0.04) were significant, and tumor substage showed a trend (p = 0.08). Taking into account the 2-year survival rates of these factors, scores for single patients ranged from 9 to 26 points. Three groups were identified: 9–13, 14–18, and 19–26 points. One-year survival rates were 8, 73, and 100 %, respectively (p < 0.001). Two-year survival rates were 0, 35, and 87 %, respectively (p < 0.001). The 3-year survival rates were 0, 19, and 75 %, respectively (p < 0.001).
Conclusion
This score including three groups with significantly different survival rates is a helpful instrument for personalization of therapy for patients with LD-SCLC. When using this instrument, the limitations if this study must be taken into account.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
Jeremic B, Dobric Z, Casas F (2011) Limited-disease small-cell lung cancer. In: Jeremic B (ed) Advances in radiation oncology in lung cancer, 2nd edn. Springer, Heidelberg, pp 491–506
Semrau S, Zettl H, Hildebrandt G et al (2014) Older patients with inoperable non-small cell lung cancer: long-term survival after concurrent chemoradiotherapy. Strahlenther Onkol 190:1125–1132
Rades D, Douglas S, Veninga T et al (2012) A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer 12:302
Rades D, Dziggel L, Segedin B et al (2013) The first survival score for patients with brain metastases from small cell lung cancer (SCLC). Clin Neurol Neurosurg 115:2029–2032
Schild SE, Tan AD, Wampfler JA et al (2015) A new scoring system for predicting survival in patients with non-small lung cancer. Cancer Med 4:1334–1343
Rades D, Huttenlocher S, Dziggel L et al (2015) A new tool predicting survival after radiosurgery alone for one or two cerebral metastases from lung cancer. Lung 193:299–302
Gazula A, Baldini EH, Chen A et al (2014) Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer. Lung 192:151–158
Foster NR, Mandrekar SJ, Schild SE et al (2009) Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 115:2721–2731
Rades D, Setter C, Schild SE et al (2008) Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 71:1134–1142
Rudat V, Stadler P, Becker A et al (2001) Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 177:462–468
Vaupel P, Thews O, Hockel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243–259
Ming X, Feng Y, Liu H et al (2015) Cardiac exposure in the dynamic conformal arc therapy, intensity-modulated radiotherapy and volumetric modulated arc therapy of lung cancer. PLoS One 10:e0144211
Turrisi AT, Kim K, Blum R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med 340:265–271
Tokuhashi Y, Matsuzaki H, Toriyama S et al (1990) Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15:1110–1113
Weltman E, Salvajoli JV, Brandt RA et al (2000) Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 46:1155–1161
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
None.
Rights and permissions
About this article
Cite this article
Rades, D., Kaesmann, L., Janssen, S. et al. A New Score for Estimating Survival After Definitive Radiochemotherapy of Limited Disease Small Cell Lung Cancers. Lung 194, 625–629 (2016). https://doi.org/10.1007/s00408-016-9886-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-016-9886-z